SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is under pressure amid concerns about declining same-store sales, softer restaurant traffic and constrained consumer spending, compounded by weakness across restaurant stocks and worries about fuel and inflation costs. Traders are split between viewing the steep selloff and fresh lows as a buying opportunity, citing franchise expansion, and expecting further downside as sales momentum weakens.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 data presented at ESMO is driving attention, with traders highlighting the triplet regimens strong progression-free survival results in PIK3CA-mutant breast cancer, especially among patients without liver metastases. The reaction is largely enthusiastic, though some debate how much the subgroup results say about the broader opportunity and note that the FDAs sNDA decision timeline remains unclear.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention mainly for technical price action, with repeated chart posts describing consolidation and traders debating whether a rebound can continue or give way to a deeper pullback. Views are mixed, ranging from bullish calls for a breakout to warnings that rallies may be corrective amid broader crypto-market weakness.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas upcoming fiscal-year results are drawing attention as the stock trades near record highs after a strong breakout. Traders are split between bullish momentum into the report and concerns that the shares are overbought and vulnerable to a pullback.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative performance versus tech-heavy indexes, with traders debating whether blue-chip strength can persist or whether weakening trends point to further declines. Rising Treasury yields and Fed policy, alongside Iran-related oil risks, are recurring concerns, while bullish traders anticipate rebounds.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Bitwise XRP ETF shares are drawing attention amid optimism over XRP-related ETF demand and regulatory clarity, alongside broader crypto-market momentum. Traders are bullish on potential institutional inflows, while others remain cautious about weak price action and confusion between the ETF and XRP itself.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

WIF is drawing attention amid persistent selling and stalled, range-bound trading, with many traders frustrated that brief rebounds fade and the token remains weak. Some see the decline as a buying opportunity and anticipate a recovery, while claims of price manipulation remain speculation.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Phase 1 atopic dermatitis results for Corvuss drug soquelitinib are driving discussion, with bullish traders citing promising efficacy signals and skeptics questioning the limited data and follow-up. The stocks decline despite the results has sparked debate over a sell-the-news reaction versus short-selling pressure.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs weaker outlook, declining sales and margin pressure have fueled a sharp selloff and fresh-low concerns. Traders are divided between buying the beaten-down shares for their dividend and long-term value and worrying about continued underperformance, leadership and dividend sustainability.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENNs steep selloff and upcoming quarterly results are driving discussion, with traders focused on whether the digital betting business can improve and criticizing management over its strategy. Some see the stock as oversold near support and anticipate a rebound, while others remain wary of further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common...

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock...

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced new data at an investor event in New York City from the ARC-20 platform study...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Companys Board of Directors...

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

Why Did Arcus Biosciences Stock Slump 10% Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The Phase 3 STAR-221 trial compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen.</li><li>Arcus Biosciences is now concentrating its development resources on its HIF-2a inhibitor, casdatifan.</li><li>The company plans to call for multiple casdatifan data readouts and study initiations throughout 2026.</li></ul>Arcus Biosciences, Inc. (RCUS), announced on Friday that it is stopping its Phase 3 STAR-221 trial after it failed to show meaningful progress.The company will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.<h2 class="st-heading-2">STAR-221 Study Discontinued</h2>The Phase 3 STAR-221 trial, which compared an anti-TIGIT and anti-PD-1 antibody duo plus chemotherapy to the established nivolumab-based regimen, did not show a survival advantage at the planned interim review.The decision marks a setback for the domvanalimab program, which was being developed alongside zimberelimab for advanced gastric and esophageal cancers.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/RCUS">Arcus Biosciences’ stock</a> traded 10% lower by mid-morning on Friday. On Stocktwits, retail sentiment around the stock changed to ‘extremely bearish’ from ‘bearish’ territory the previous day. Message volume changed to ‘high’ from ‘normal’ levels in the last 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:930/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_112646_png_edcaeadd11.webp" alt="RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits" width="930" height="106"><figcaption>RCUS’s Sentiment Meter and Message Volume as of 11:15 a.m. ET on Dec. 12, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Refocusing On Casdatifan</h2>With the STAR-221 trial ending, Arcus is concentrating its development resources on its HIF-2a inhibitor, casdatifan, which has shown encouraging single-agent results in clear cell renal cell carcinoma (ccRCC) studies.&nbsp;Early data demonstrated meaningful improvements in key measures such as response rates and progression-free survival in over 120 patients, and plans call for multiple casdatifan data readouts and study initiations throughout 2026.&nbsp;<blockquote>“The results from STAR-221 are not what we had hoped for, and we have important work ahead to meet the needs of patients on our domvanalimab studies and also accelerate the casdatifan and I&amp;I programs.”-Terry Rosen, CEO, Arcus</blockquote>RCUS stock has gained over 51% in 2025 and over 31% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fuzzy-panda-shorts-new-era-energy-and-digital-stock-we-believe-it-is-gray-s-next-flameout/cLICVVRREFy">Fuzzy Panda Shorts New Era Energy &amp; Digital Stock: ‘We Believe It Is Gray’s Next Flameout’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A scientist introduces liquid into a test tube at the Zamudio Technology Park laboratory in Bilbao.

Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$18.54
Prev Close	$19.36
Open	$19.02
Dividend Yield	0.00%
50-Day Moving Average	$26.12
Beta	1.57
Avg. Volume	1.74M
PE Ratio	-4.75

52-Week High	$31.74
52-Week Low	$17.43
Market Capitalization	$2.36B
EPS (Annual)	-$3.29
Price to Book	5.07
Revenue Per Employee	$410,981.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCUS Fundamentals